Author:
Cupido A. J.,Stoekenbroek R. M.,Kastelein J. J. P.
Publisher
Springer International Publishing
Reference148 articles.
1. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet [Internet]. Elsevier BV; 2004;364(9438):937–52. Available from: doi: 10.1016/s0140-6736(04)17018-9 .
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (London, England) [Internet]; 2005 [cited 2016 Apr 28];366(9493):1267–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16214597
3. Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation [Internet]. Ovid Technologies (Wolters Kluwer Health); 1992;85(6):2025–33. Available from: doi: 10.1161/01.cir.85.6.2025 .
4. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation [Internet]. Ovid Technologies (Wolters Kluwer Health); 1989;79(1):8–15. Available from: doi: 10.1161/01.cir.79.1.8 .
5. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ [Internet]. BMJ 2009;338(feb16 1):b92–b92. Available from: doi: 10.1136/bmj.b92 .